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ABSTRACT 
The purpose of this study was to characterize the immune response involved 
in the development and resolution of colitis induced by S. hyodysenteriae-infection in 
mice. Treatment groups included mice which were (1) vaccinated with a pepsin 
digest of S. hyodysenteriae strain 8204, (2) infected with S. hyodysenteriae strain 
8204, (3) vaccinated and infected, or (4) non-vaccinated and non-infected. Twenty-
two days postchallenge, cecal lesions were less severe in vaccinated mice as 
compared to cecal lesions in non-vaccinated mice. To determine the type of immune 
response elicited, S. hyodysenteriae-specific serum antibody (lgG2a & lgG1) and in 
vitro cytokine (IFN-y and IL-10) production by splenic and mesenteric lymph node 
cells were measured. Infection induced higher levels of S. hyodysenteriae-specific 
lgG2a than lgG1. Intramuscular immunization with the pepsin digest of S. 
hyodysenteriae caused a resolution of the cecal lesion. Successful vaccination also 
resulted in a down regulation of the S. hyodysenteriae-specific lgG2a 22 days 
postchallenge when compared to non-vaccinated, infected mice. Vaccination also 
induced higher S. hyodysenteriae-specific lgG1 as compared to infection alone. In 
addition, in vitro stimulation of spleen cells with S. hyodysenteriae antigen resulted in 
less IFN-y production by cells isolated from vaccinated, infected mice as compared 
to cells isolated from non-vaccinated, infected mice. Following challenge, the IL-10 
production by mesenteric lymph node cells was higher in the vaccinated group than 
the non-vaccinates. These data showed that pepsin digest vaccination reduces S. 
x 
hyodysenteriae lesion severity by dampening lgG2a and IFN-y responses to S. 
hyodysenteriae antigens with a subsequent increase in the lgG1 and IL-10 
production in the vaccinated animals. These results suggested that in order to 
overcome or ameliorate the colitis induced by this microorganism, immune 
regulation of the dominant Th-1 response induced following infection is required and 
the necessary regulatory mechanisms can be induced by immunization with a 
pepsin-digested bacterin. 
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INTRODUCTION 
A major category of intestinal inflammation in humans has been identified as 
inflammatory bowel disease (IBD), with two major forms known as Crohn's disease 
(CD) and ulcerative colitis (UC) (6). Because of the importance of IBD, studies 
using animal models have been conducted to define the causative agent(s), 
pathogenesis, prevention and treatment for these diseases (14, 31, 36, 58). These 
animal models were used to study the acute and the chronic phases of intestinal 
inflammation, but none were considered a perfect experimental IBD model (136). 
This lack of a perfect animal model has resulted in the inability to clearly identify the 
initiating factor(s) as well as the pathogenesis of these diseases. Despite this fact, 
the available animal models successfully illustrate the role of the inflammatory 
process in colitis. Chronic intestinal inflammation in humans, mice, pigs and other 
animals could occur as a result of either persistent infection, an impaired epithelial 
cell barrier or failure to regulate the mucosa! immune response (31, 73). Each of 
these mechanisms could be affected by genetic factors (58, 73). However, the 
exact mechanism that controls the inflammatory process or the distribution of 
inflammation in the intestine is still unknown. 
1 An aberrant immune response has been shown to contribute to many 
disease processes (e.g., Leishmania infections) (67). This immune response 
consists of cell-mediated and humoral immune responses which are controlled by 
two functional subpopulations of T-helper subsets (i.e., Th-1 and Th-2 cells) (5, 29, 
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87). The Th-1/Th-2 concept has been utilized to understand the regulatory effect of 
these two cell types in inflammatory diseases (22, 46). For example, T-cell 
responses have been considered a key factor underlying the pathogenesis of IBDs. 
In most cases, dysregulated or excessive T-cell responses associated with IBD 
have been characterized as Th-1 in nature. In addition, the existence of pro-
inflammatory cytokine (e.g., IFN-y, TNF-a and IL-1) which is a feature of Th-1 
response was associated with either the onset or the maintenance of lesions (31, 
43, 73, 110, 116, 138). 
The regulation of these Th-1 responses was simply described as the 
activation of antagonistic cell(s) (i.e., Th-2). Th-2 cells were defined as T cells that 
secrete cytokines including IL-4 and IL-10. These cytokines have been shown to 
ameliorate inflammatory responses (1, 89, 119, 129, 137). Recent developments in 
IBD research correlate the Th-1/Th-2 dialog to the pathological changes that occur 
in these diseases (31, 43, 73, 110, 116, 138). These studies attempt to model the 
classical paradigm for Th-1/Th-2 cross-regulation in which the two cells were 
described as "competing T-helper subsets", producing autocrine proliferative 
cytokines (e.g., IL-2 and IL-4) as well as cross-regulatory cytokines (e.g., IFN-y and 
IL-10). Further studies of these cell interactions have led to a wider and better 
understanding of the involvement of T-helper subsets in disease. Thus, it is better 
to define the Th-subset interaction on the basis of choosing the proper effector 
immune function, whether it involves Th-1, Th-2 or both responses, rather than on 
the basis of immune polarization (93). 
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Intestinal lesions in mice infected with S. hyodysenteriae (i.e., the causative 
agents of swine dysentery), may have immunological features resembling those 
found in IBDs (45). The development of a Th-1 response was demonstrated in 
animals infected with S. hyodysenteriae (45). This Th-1 response was identified by 
elevated serum levels of lgG2a, an antibody produced through the activation of Th-
1 cells. In addition, in vitro cytokine production showed that these mice developed 
a Th-1 immune response characterized by the induction of TNF-a and IFN-y by 
cecal mucosa and mesenteric lymph node cells, respectively (45). 
Swine dysentery (SD) is considered to be an economically important 
disease with a worldwide distribution (143). The economic losses associated with 
SD not only include morbidity and mortality but also the cost of chemotherapeutic 
agents used to control the disease (143). In addition to antibiotics, vaccination has 
been proposed as a mechanism to control SD. However, previous reports have 
indicated that vaccination only provides partial protection and it may even 
exacerbate the onset of the lesions (39, 109). In order to develop a more effective 
vaccine, it is necessary to better characterize the immune-mediated mechanisms 
contributing to the pathogenesis of SD (143). 
Previous studies have examined the pathogenesis of SD in immunologically 
na'ive animals. The objective of this study was to determine the mechanisms of 
protection induced by the parental immunization of mice with a proteinase-digested 
vaccine. The ability of the vaccination regimen to alter the development of the Th-1 
response was examined. Using measures of humeral and cellular immunity, Th-1 
4 
and Th-2 immune responses were assessed in naive and immunized animals 
following challenge with S. hyodysenteriae. This approach will permit the 
assessment of these responses in the disease process and determination of the 
relationship between the Th-1 and Th-2 cells. 
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LITERATURE REVIEW 
Th-1/Th-2 Concepts in Diseases 
Traditionally, immune responses have been viewed as either cell-mediated 
or humeral in nature. As our knowledge of the immune response has increased, 
this simple perspective has revealed much more complex interactions. As a 
complete review of immunology would be too lengthy for this discussion, the 
literature review focuses on advancements in T-cell interactions. 
Evolution in immunology has suggested that the development of 
differentiated antigen-specific immune responses is dependent upon selective 
activation of particular subsets of CD4+ helper T-cell population (22, 27, 29). In 
murine studies, these CD4+ T-helper cells were initially divided into two 
subpopulations with contrasting and cross regulating cytokine profiles (5, 22). 
These T-helper cell subsets were referred to as either T-helper type 1 (Th-1) or T-
helper type 2 (Th-2) cells according to the cytokines produced and the immune 
response in which they participated (Table 1) (5, 29, 87). For example, Th-1, but not 
Th-2 cells, secrete IL-2, TNF-a and IFN-y while Th-2 cells mainly produce IL-4, IL-5, 
IL-6 and IL-10 (29, 46, 93). The distinct cytokine profiles that are produced by one 
cell type and not from the other lead to the hypothesis that distinct effector functions 
are segregated with the Th-1 and Th-2 cells (87). Generally, Th-1 cells through IFN-
'Y production, participate in cell-mediated immune responses such as delayed type 
hypersensitivity reaction (DTH), phagocytic cell recruitment and activation and 
6 
proliferation of lymphocytes (5, 19, 29, 93). On the other hand, Th-2 cells are 
correlated with the induction of humoral immune responses by releasing a variety 
of cytokines (i.e., IL 4, IL 5, IL 6 and IL 10) that lead to immunoglobulin synthesis 
(i.e., lgG1, lgA and lgE). However, these functional distinctions are not absolute as 
Th-1 cells have been shown to induce murine lgG2a synthesis (5, 22, 27). Thus, 
Th-1 and Th-2 cells are considered to be regulatory cell types that affect most if not 
all immune cells. 
Table 1. T helper cell types and their cytokine production 
Cell type Th-1 Th-2 Th-3 
Cytokine production TNF, IFN-y, IL-2 IL-4, IL-5, IL-6, IL-10 TGF-~ 
Effector function Cell-mediated immunity Humoral immunity Immune suppression 
and humoral immunity (e.g., lgG1, lgA, lgE) and oral tolerance 
(e.g., lgG2a) 
Recently, a third T helper subpopulations was described. These cells were 
defined as transforming growth factor-~ (TGF-~) producing cells or Th-3 cells 
(Table 3). The TGF-~ is an inhibitory cytokine and is considered a key regulator of 
inflammation occurring in response to infectious and autoimmune diseases (42, 
53) as well as experimental colitis (96). Some studies indicated paracrine and 
autocrine action of this cytokine on intestinal epithelial cells (96). The regulation of 
TGF-~ production is not as well defined as IL-4 or IFN-y cytokine production (129). 
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Several studies showed that the priming conditions needed for the induction of 
TGF-~-producing cells resembled those conditions required for Th-2 cells, namely 
low amounts of IL-12 and IFN-y and high amounts of IL-4. Thus, TGF-~ production 
could be enhanced by neutralization of IL-12 and IFN-y (129). Some studies also 
demonstrated that TGF-~ administration clearly inhibited the generation of a Th-1 
response and IFN-y production (53). Furthermore, Th-2 cells may be considered an 
accelerating force behind TGF-~- producing cell development as a consequence of 
IL-4 or IL-10 secretion (129, 137). In vitro, the addition of IL-10 in the presence or 
absence of anti-IL-4 led to a threefold increase in production of TGF-~ (137) . This 
indicates that TGF-~ production can occur independent of the Th-2 response but 
the presence of Th-2 cells may aid in TGF-~ production (129, 137). 
T helper cells not only exhibit distinct functional properties, but they also 
have an antagonistic action towards each other (5). For example, cytokines (e.g., 
IFN-y) produced by Th-1 cells may down-regulate the production of cytokines (e.g., 
IL-4, IL-10) by Th-2 cells (88). Applying this concept in experimental animal 
models, a number of diseases can be prevented by influencing the development of 
the normal Th-1 or Th-2 response (5, 27, 83, 90, 134). For example, studies of 
Leishmania infection in mice have been helpful in defining this functional aspect of 
cytokine responses. In murine leishmaniasis, a bias toward a Th-2 response was 
correlated with susceptibility to infection (27, 46, 67, 69, 70). Within 72 hr after 
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infection, the susceptible strains of mice (e.g., BALB/c) developed a biased Th-2 
response, characterized by the generation of IL-4 and IL-5. This biased Th-2 
cellular response as well as protection from disease could be adjusted through the 
injection of anti-IL-4 monoclonal antibody or through the expansion of the IFN-y 
producing T cells as demonstrated in resistant strains of mice (e.g., C3H) (67, 69). 
An altered immune response or biased Th-1 or Th-2 response can also be 
correlated with other diseases. For instance, a biased Th-2 response has been 
correlated with some disorders such as systemic lupus erthematosis, progressive 
systemic sclerosis or allergic diseases, whereas a dominant Th-1 response has 
been associated with many chronic inflammatory disorders or autoimmune 
diseases (27). However, in many other disorders Th-1/Th-2 involvement is less 
prominent or has not been well defined (27). It is more appropriate in some cases 
to define the combinations of functional effector cells required for the induction of 
protective immunity rather than classifying Th-1 type or Th-2 type responses (2). 
While unregulated responses are deleterious, both Th-1 and Th-2 responses have 
an important role in health (i.e., avoiding undesirable immunopathological 
responses) and recovery from many diseases or disorders (2, 27). 
The identification of Th-1/Th-2 patterns produced during different stages of 
disease could provide insight into the mechanisms that underlie the basis of 
resistance or susceptibility ( 134). Th-1 dominant responses are potentially effective 
in eradicating infectious agents including intracellular pathogens. When Th-1 
responses are inappropriately activated, host tissue damage may result (27). In 
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contrast, the antibody response that results from Th-2 activation may be insufficient 
to provide protection against the majority of infectious agents (i.e., intracellular 
pathogens). However, antibody responses generally provide protection against 
parasites, viruses and toxin-producing bacteria (27, 63, 102, 132). Th-2 responses 
are also helpful in limiting potentially harmful Th-1 mediated responses (46). 
Hence, Th-2 activation may have a regulatory response in addition to its role in 
antibody production. Accordingly, these two T-cell populations are currently at the 
heart of research in almost every area of infectious disease, cancer, 
transplantation, neonatal tolerance and autoimmunity (2). 
Th-1 and Th-2 differentiation signals 
Ontologically, Th-1 and Th-2 cells could be derived from either one common 
or from two different precursors (22, 27). Data generated from a murine immune 
system suggested that Th-1 and Th-2 cells are derived from stimulated memory T 
cells that are already mature and differentiated from a single precursor pool. Naive 
CD4+ T cells that leave the thymus must be stimulated with appropriate activation 
signals in order to terminally differentiate into either Th-1 or Th-2 cells (22). 
The development of Th-1 or Th-2 responses also depends on environmental 
factors including dose of antigens, physical nature of the immunogen, the type of 
adjuvant and cytokines present at the time of antigen presentation (e.g., IL-2, IFN-y, 
or IL-4) as well as other undefined genetic factors (22, 27, 138). For example, a 
high dose of antigen administrated to TCR-transgenic mice favored the 
development of Th-2 cells while a low to medium dose facilitated Th-1 
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differentiation (22, 27). However, using an extremely low dose of antigen induced a 
dominant Th-2 cell response (27). In addition to the dose effect, the presence of 
certain co-stimulatory molecules on antigen presenting cells (APC) or on T cells 
may affect Th-cell differentiation (27, 29, 46). For instance, 87.2 on APC 
(macrophages, dentritic cells (DC) or B cells) direct T-cell differentiation towards a 
Th-2 phenotype (22, 27) while the presence of CD40 ligands (L) on activated T 
cells promotes Th-1 cell responses (27, 66, 76). Other surface molecules 
expressed at the time of T-cell priming, such as OX-40L and CD40 expressed by 
dentritic cells (DC) or activated B cells, may also provide Th-2 or Th-1 determining 
signals, respectively (66, 76). In human T-cell differentiation, the interaction 
between CD30L on T cells and CD30 on APC direct Th-2 differentiation, whereas 
blocking this interaction with either an anti-CD30L or CD30-lg fusion protein 
promoted the development of Th-1 cells (27). CD8+ T cells have also been shown 
to affect the development of these two distinct types of CD4+ T-helper cells (i.e., Th-
1 and Th-2). For example, secretion of IFN-y by CD8+ T cells induces production of 
IL-12 by DC. IL-12 has been shown to be a critical cytokine in the induction of Th-1 
responses (27). Likewise, IL-4 production by mast cells, basophils and CD4+ 
NK1 .1 +cells (i.e., CD4+ T cells express the NK1 .1 antigen) early in the immune 
response favor the development of Th-2 cells (1, 17, 66, 89, 119, 160). 
Other factors, such as the choice of adjuvants, could direct T-cell 
differentiation. The use of Freund's incomplete adjuvant or alum has been shown 
to favor development of either a Th-1 type of response or a Th-2 response, 
1 1 
respectively (27). Some studies have also shown that corticosteriods could 
enhance the capacity of macrophages to induce Th-2 cytokine synthesis by 
inhibiting IL-2 production (26). It is also clear that the inhibitory effect of 
dexamethazone treatment is more marked on Th-1 cytokines synthesis than on Th-
2 cytokines (63). Differentiation of T-helper cells into Th-1 and Th-2 cells are 
regulated by the glutathione level in APC. It has also been found that glutathione 
depletion in APC populations causes a shift from a typical Th-1 cytokine profile 
toward a Th-2 response (111 ). In aggregate, these studies indicate that the signals 
required for T-cell differentiation into Th-1 or Th-2 are not only distinct, but have an 
antagonistic effect. 
Th-1/Th-2 concepts in inflammatory bowel diseases 
By using animal models of colitis, it may be possible to expand our 
understanding of the processes that control mucosal inflammation as well as the 
involvement of Th-1/ Th-2 responses in gastrointestinal disease. The organized 
mucosal lymphoid tissues have a large number of T cells. These cells respond in 
numerous ways to a variety of microbes that colonize the intestine. T cells 
encounter the immunogen and deal with these microbes in the inductive sites of 
the intestine which include Peyer's patches (PP), the lymphoid nodules of the small 
intestine and the colon (108). The PP are considered a sampling site for luminal 
antigens that enter through M cells (38, 108). Generally, ingested protein evokes a 
Th-1 cell response (i.e., IFN-y) in mucosal lymphoid follicles. These proteins are 
presented to the T cells by antigen presenting cells (e.g., dentritic cells). Following 
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antigen presentation, T cells become activated, leave the PP, and recirculate to 
effector compartments of the intestinal mucosa (e.g., lamina propria and intestinal 
epithelium) (75). In order to prevent the unnecessary activation of an immune 
response, Th-1 responses are controlled by a mechanism of immune suppression 
or tolerance (e.g., production of TGF-P in vivo or experimentally by anti IL-12 
treatment) (85, 129, 137). For example, T lymphocytes found within the follicular 
region of murine PP have a similar frequency of Th-1 or Th-2 cell types. While in 
the lamina propria, Th-2 cells are predominant (141 ). This high number of Th-2 
cells is important to facilitate the class switching of B cells to produce different 
isotypes of antibodies, such as lgG1, lgE and lgA (141 ). Afterward, this 
predominant Th-2 response may also be required for the regulation of the Th-1 
response in the effector compartment of the intestine (i.e., lamina propria). 
Early in the immune response, Th-2 responses within the PP have been 
shown to control unwanted Th-1 cell differentiation from precursor cells (Th-0) (71). 
Nevertheless, once Th-0 cells have differentiated toward a Th-1 phenotype, Th-2 
cells act in synergy with TGF-P producing T cells (i.e., Th-3 cells) to down-regulate 
activation of Th-1 cells (71 ). At the same time, these Th-2 retain their down-
regulatory effect on further Th-1 cell development from precursor cells (Th-0) (71 ). 
Several studies have proposed that Th-2 cells are important for Th-3 activity. These 
studies showed that the initial induction of TGF-P from Th-3 cells does not require a 
Th-2 response, but the augmentation of this cytokine production is probably 
affected by IL-4 or IL-10 produced from Th-2 cells. Alternatively, IL-4 or IL-10 may 
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act as a growth factor for TGF-~ producing cells rather than as inducing factors 
(129, 137). 
The Th-1 and Th-2 dialog has been correlated to the pathological changes 
that occur in humans IBDs and several mouse models for colitis (31 , 43, 71, 73, 
110, 116, 138). It is important to point out that most of these studies clarify that 
neither Tor B cells nor T-cell derived cytokines play a role in early acute colonic 
injury (31 ). The induction of a local DTH reaction is believed to be a major 
component of IBD where a Th-1 response was considered a core of this reaction 
(73). This may indicate that other mechanisms are involved in the induction of the 
inflammatory disease process that predisposes to a biased Th-1 inflammatory 
response. These studies also proposed the hypothesis that IBD results from a 
dysregulated Th-1 cell response to ubiquitous mucosal antigens that are not 
appropriately controlled by a normal regulatory mechanism (i.e., Th-2 or Th-3 
cells). In other words, a predominant Th-1 cell response that is found within the 
lamina propria can be correlated with tissue damage. Because the lamina propria 
is exposed to a variety of antigens derived from the intestinal lumen, a lymphocytic 
response towards these antigens may activate Th-1 cells and IFN-y production 
(73). This cytokine may, in turn, cause the activation and recruitment of phagocytic 
cells as well as other inflammatory cells (73). These data suggest that activated T 
cells, especially those expressing a Th-1 cytokine profile, play an important role in 
the pathogenesis of IBD. In addition, one could also hypothesize that regulating the 
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number of Th-1 cells present in the lamina propria should minimize the degree of 
inflammation and affect the resolution of the inflammatory reaction. 
Generally, the importance of Th-2 mediated regulation for Th-1 cells may be 
applied in the inflammatory disease of the bowel which may be considered as an 
intermediate step that shifts a Th-1 response in the mucosa to TGF-~ producing 
cells (129, 137). Through an understanding of the role of Th-1 or Th-2 cells in 
particular diseases, it will be possible to utilize pharmacological or biological 
approaches to enhance or inhibit Th-1 or Th-2 cellular response (134, 149). For 
instance, anti-inflammatory drugs are widely used for colitis resolution in animal 
models and for treatment of human IBD. The successful outcome of these drugs 
supports the involvement of immune processes in the development as well as 
resolution of local inflammation of the intestine (148). 
The biased Th-1 response in the disease process is either initiated or 
maintained by the presence of antigens derived from the microflora and may be 
perpetuated once it has begun (71 , 135, 150). It is important to re-establish 
mucosal homeostasis once the disease process has begun (71 ). Therefore, 
therapeutic protocols, which result in regulation of aberrant Th-1 responses, should 
have major benefit in the control of immune-mediated inflammation. 
lmmunopathological Response in Inflammatory 
Disease of the Bowel 
Whether occurring in humans, mice or pigs, inflammatory diseases of the 
bowel can be described as extensive infiltration of immune cells in response to one 
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or more etiological agents. In humans, the two common types of inflammation are 
ulcerative colitis (UC) and Crohn's disease (CD) (6, 73). In UC, the inflammation is 
limited to the large bowel and is marked by superficial and continuous 
inflammation beginning from the recto-sigmoid colon and extending proximally 
where clinical signs are mainly ulcers and bleeding. Ulcerative colitis is also 
characterized by an extensive infiltration of the mucosa and submucosa with 
neutrophils, macrophages, and lymphocytes. Compared to UC, CD is 
characterized by granulomatus infiltration that extends through all the layers of the 
bowel wall rather than being confined to the mucosa or submucosa. Crohn's 
disease mainly affects the terminal ileum and cecum in a discontinuous or 
segmental pattern. Clinically, this form of IBD is associated with intestinal 
obstruction as well as fistula and abscess formation. In addition to these clinical 
and pathological differences, the two diseases also have immunological 
differences. For instance, CD is described as a Th-1 driven inflammation 
characterized by high IL-12 and IFN-y production, whereas UC is mainly classified 
as Th-2 driven inflammation due to the presence of high IL-5 (11, 14, 44, 116, 157). 
Furthermore, the intestinal inflammation associated with UC indicates the 
involvement of both T cells (Th-2) and B cells in the pathogenesis of this disease 
(116). B cells may be involved as a consequence of the production of auto-
antibodies (116). In addition, pro-inflammatory cytokine production (e.g., IFN-y, IL-
12, IL-2, TNF-a) in UC shows a slight to no change, while IL-10 is elevated. This 
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appears to be exactly opposite as to that which has been described for CD (9, 92, 
94, 116). 
The etiological agents for UC and CD have not been identified (6, 73, 115, 
116). It has been suggested that the inflammatory events in human IBD may begin 
by an initiating factor(s) including an interaction between genetic, environmental 
and immunological factors (6, 32, 58, 73, 115). It has also been postulated that the 
onset of human IBD may involve any number of infectious agents or toxins affecting 
the mucosal barrier (32, 35, 77, 112). This breach in the epithelium may induce an 
inflammatory response that can become chronic in a genetically susceptible host 
(32, 58). Genetic factors may also influence the way that macrophages process 
antigens. The responding macrophages will produce IL-1 and other cytokines that 
induce a sequence of immune events involving T-cells and B cells. This cellular 
activation may exacerbate the epithelial cell damage in inflammatory diseases of 
the bowel (73). This could occur through the activation of cytotoxic T cells, NK cells 
and B cells that result in antibody production as well as complement activation. In 
addition, the activated T cells will cause more macrophage activation that aid in 
additional cellular damage (73) . 
In conclusion, the critical steps in the development of IBD involve a deviation 
from immune activation to inflammation and nonspecific destructive processes of 
the body. Therefore, the development of therapeutic protocols that results in the 
resolution of IBD will come from an increased understanding of the immune 
regulation occurring within the gastrointestinal tract, and the regulatory 
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mechanisms that have the ability to ameliorate inflammatory responses within the 
intestine. 
The Role of Cytokines in Inflammatory Bowel Diseases 
Extensive studies have been conducted on the central role cytokines play in 
the modulation of mucosal immunity and correlation to IBD (65, 74, 120, 134, 138). 
Cytokines are produced by different types of cells including lymphocytes 
(especially T cells of the Th-1 and Th-2 phenotypes), monocytes, macrophages, 
granulocytes, epithelial cells, endothelial cells, and fibroblasts (120). They can 
have either pro-inflammatory functions (interleukin-1 (IL-1 ), tumor necrosis factor 
(TNF), IL-6, IL-8, IL-12) or anti-inflammatory functions (IL-4, IL-10, IL-11, 
transforming growth factors (TGFs)) (94). Studies have shown that the availability of 
and relationships between these cytokines can determine the nature of the immune 
response to disease (36, 120, 122). The inflammatory response in most diseases 
can be induced, amplified, prolonged or terminated by cytokines (120). In the 
mucosa of patients with IBD (e.g., Crohn's disease (CD), ulcerative colitis (UC), 
diverticulitis, and infectious colitis) , an imbalance has been observed between pro-
inflammatory and anti-inflammatory cytokines (i.e., too much IFN-y or too little IL-4) 
(65, 74, 134, 138). Many studies have also demonstrated that inhibition of pro-
inflammatory cytokines and/or supplementations with anti-inflammatory cytokines 
can reduce inflammation in some animal models of colitis and in some cases of 
IBD in humans (30, 120, 123, 127, 148, 149, 151). 
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lmmunoregulatory cytokines 
Cytokines such as IL-2, IL-4 and IL-10 have important immunoregulatory 
effects (58, 94, 101, 120). IL-2 is mainly secreted by the Th-1 subset of T-helper 
cells. It induces T-cell proliferation via autocrine or paracrine actions (33, 46). IL-4, 
also known as B cell stimulatory factor, is mainly synthesized by activated 
lymphocytes, NK cells and mast cells (46) . It also has immunoregulatory and anti-
inflammatory activities and may play a central role in gastrointestinal immunology 
( 103). Evidence of insufficient production or abnormalities in immunoregulatory 
cytokine expression may be used to correlate the immune dysregulation with 
pathogenic events (120). IL-4 levels (i.e., IL-4 mRNA) were found to be reduced in 
IBD (62), although this reduction is more obvious in CD than in UC (44, 101 ). On 
the other hand, samples from CD patients showed elevated levels of IL-2 (11, 102, 
117) while UC patients showed decreased levels (94). Thus, it was postulated that 
CD is a Th-1-mediated disease on the basis that IL-2 is a Th-1 cytokine and IL-4 is 
a Th-2 cytokine (93). Based on these observations one may conclude that CD and 
UC result from separate immunopathogenic mechanisms (120). 
Another immunoregulatory cytokine that may play a vital role in IBD is IL-10. 
Interleukin 10 is produced by T cells (130), B cells(106), or monocytes activated by 
lipopolysaccharide (LPS) (86) . lnterleukin10 inhibits IFN-y production by Th-1 cells, 
the antigen-presenting function of monocytes/macrophages and the production of 
pro-inflammatory cytokines from activated macrophages (25, 40, 41 ). The role of IL-
10 in IBD has been demonstrated in vitro. For example, the addition of IL-10 to the 
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culture of mononuclear phagocytic cells from an IBD patient resulted in a down 
regulation of the phagocytic activity of these cells (127). Th-1 cells require antigen-
presenting cells and, thus, are more susceptible to regulation by IL-10. Interleukin 
10, particularly, down-regulates the production of Th-1 cytokines (e.g., IFN-y and IL-
2) whereas Th-2 cytokines, such as IL-4 and IL-5, seem to be less affected (41 ). 
Moreover, IL-10 enhances the production of anti-inflammatory mediators such as 
I L-1 receptor antagonists (25, 40). 
Recent research interest in IBD has focused on the anti-inflammatory and 
regulatory properties of IL-10 (120, 127). The important role of IL-10 in mucosal 
homeostasis has been demonstrated by examining IL-10-deficient mice (120). 
These mice developed spontaneous chronic enterocolitis that could be resolved by 
the administration of exogenous IL-10 (65). Chronic intestinal inflammation in 
patients with CD showed a slight increase in IL-10 mRNA expression in association 
with the characterized Th-1 cytokine production (6). This may indicate that IL-10 is 
an important regulatory component that should be up-regulated in order to control 
the inflammatory response in IBD specially CD(6). This information suggests that 
the disparate T-cell effector functions are carried out by T-cell subsets secreting 
defined patterns of cytokines (i.e., IL-10 and IL-4 from Th-2 and IL-2 from Th-1) (44). 
Pro-inflammatory cytokines 
An inadequate or prolonged activation of the intestinal immune system plays 
an important role in the pathophysiology of chronic mucosal inflammation (43, 120, 
124). Chronic elevation of pro-inflammatory cytokine (e.g., IFN-y, TNF-a, IL-1 ~. IL-6) 
20 
production has been demonstrated in most models or cases involving inflammatory 
disease of the bowel (43, 120). An excess production of these cytokines leads to 
the destructive features associated with mucosal inflammation (120). Studies on 
the importance of pro-inflammatory cytokines, such as IL-1 or IL-1 p and TNF-a in 
the inflammatory process especially in CD, are either less important when 
compared to other cytokines or have shown contradictory results (113, 120). For 
example, the expression of IL-1 p or IL-1 p mRNA level has been shown to increase 
in inflammatory lesions of patients with CD but this increased expression is not 
considered a disease-specific event since it has also been found in patients with 
diverticulitis or severe infectious colitis (78, 117, 120, 161). 
Tumor necrosis factor alpha is an important mediator of inflammation. It 
shares many pro-inflammatory activities with IL-1 (120). In contrast to IL-1, the data 
available regarding the expression of TNF-a in IBD are inconsistent (120). Some 
groups were able to demonstrate increased levels of TNF-a (3, 10), whereas others 
were unable to detect increased expression of TNF-a in-patients with IBD (3). 
These contradictory findings may result from difficulties to detect the increased 
level of mucosal TNF-a in IBD or may be related to the stage of the disease (120). 
A recent study using the mouse model of colitis induced by S. hyodysenteriae 
showed that local expression of mRNA TNF-a in the lamina was only slightly 
increased (i.e., 1.5 to 2-fold) which may indicate that small changes could have a 
biological significance (68). 
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Interferon gamma is considered one of the most important pro-inflammatory 
cytokines that also has an immunoregulatory action (120, 124). Interferon gamma 
produced by Th-1 lymphocytes and NK cells (93, 120) is one of the most potent 
activators of mononuclear phagocytes, increases MHC class I and II expression, 
promotes T and B cell differentiation, and activates neutrophils, NK cells, and 
vascular endothelial cells (120). The level of IFN-y has been found to be elevated 
in the intestinal mucosa of CD and UC patients, as well as in animal models for 
colitis (138). Interferon gamma is considered a key pro-inflammatory cytokine that 
has a highly destructive effect in the mucosa of the intestine in CD (37, 125). It has 
numerous biological effects, including activation and recruitment of neutrophils and 
macrophages to the site of the inflammation (80). This introduction of phagocytic 
cells with persistent activation of these cells from residential unknown causative 
agents as in CD will cause more pro-inflammatory cytokine production such as IL-1 
and TNF-a. The outcome of this cyclic activation is the exacerbation of the 
inflammatory reaction at that site. 
Another important cytokine that plays a role in human IBD especially in CD 
as well as in animal models of colitis (i.e., TNBS mouse model) is IL-12 (120). 
Interleukin 12 is mainly produced by antigen-presenting cells (120). This cytokine 
induces the rapid production of IFN-y by natural killer cells and T cells and in 
association with IFN-y promotes the differentiation of the naive Th cell into Th-1 
cells (23, 52, 126, 128, 146). Both IL-12 and IFN-y may be considered the driving 
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forces behind murine intestinal inflammation (138). Several studies have 
suggested that the absence of adequate counter-regulatory mechanisms leads to 
excessive secretion of IL-12 and the induction of an overt Th-1 response marked by 
IFN-y production (138). 
Together, these findings suggest that a poorly regulated Th-1 T-cell 
response is the key mechanism underlying the pathogenesis of CD and other 
models of colitis (138). The regulation of an inappropriate Th-1 response may be 
achieved through the activation of antagonist regulatory cells as Th-2 cells. When 
Th-2 cells are elicited in vivo, IL-4 and IL-10 will be produced with a subsequent 
down-regulation to the Th-1 response 
Regulatory effects of transforming growth factor-~ 
Another mechanism that takes place in the regulation of disease process is 
when a low dose of antigen is ingested or when a low dose of antigen entering the 
mucosa! immune system via mucosa! follicles induces T cells to produce non-
specific suppressor cytokines, such as transforming growth factor-~ (TGF-~) as well 
as production of IFN-y from Th-1 cells. In most cases, the TGF-~ effect 
predominates and a state of oral tolerance occurs followed by immune suppression 
(154, 155, 156). The TGF-~ is an inhibitory cytokine and is considered a key 
regulator of inflammation occurring in response to infectious and autoimmune 
diseases (42, 53) as well as experimental colitis (96). Some studies indicated the 
paracrine and autocrine action of this cytokine on the intestinal epithelial cells (96). 
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Studies in murine models strongly suggested that the overproduction of pro-
inflammatory cytokines is associated with inadequate secretion of the counter 
regulatory and anti- inflammatory cytokines such as TGF-P (137). Some 
observations showed that TGF-P producing cells inhibit the pathologic 
inflammatory response while administration of anti- TGF-P either abrogates the 
protective effect of oral tolerization or exacerbates the underlying inflammation (47, 
82,116). 
Regulatory action of cytokines 
As discussed earlier, the dysregulated and excessive Th-1 T-cell response 
in CD is characterized by increased IL-12 production by antigen-presenting cells 
followed by increased IFN-y production by CD4+ T cells (138). Interferon gamma 
then acts on macrophages to induce the production of pro-inflammatory cytokines, 
such as TNF-a, IL-6, and IL-1 p (12). Finally, TNF-a and IFN-y produced during Th-1 
T cell responses act in synergy to "back-stimulate" further production of interleukin-
12 by antigen-presenting cells; this positive feedback effect amplifies and sustains 
the Th-1 T-cell-mediated inflammatory response (147). It appears that IFN-y is a 
necessary mediator of colonic inflammation while TNF-a with other pro-
inflammatory cytokines are critical components of the effector phase of colonic 
inflammation (138). On the other hand, other studies showed that either the 
inhibition of the synthesis of these cytokines at the messenger RNA level (97) or 
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gene knockout of these cytokines (e.g., IFN-y or IL-12) in some animal models 
resulted in preventing the development of colitis in these animals (24). 
Currently, little is known about the precise effective concentration required of 
these immunoregulatory and /or anti-inflammatory cytokines, such as IL-2 and IFN-
'Y (Th-1 cytokines) or IL-4 and IL-10 (Th-2 cytokines) in the intestinal mucosa of 
patients with IBD (102). An increase of one or more of these cytokines may lead to 
either protection or development of an immunopathological reaction ( 102). Th-1 
cytokine profiles are more involved in the pathological promotion of lesions in CD. 
Thus, in order to maintain an appropriate immune response and to counteract the 
effects of pro-inflammatory cytokines present in the inflamed mucosa of patients 
with CD, increased IL-10 levels and other anti-inflammatory cytokines such as IL-4 
and TGF-~ might be important in the down-regulation of inflammation (137). At the 
same time, increased Th-2 cytokine levels should also be limited to avoid a biased 
Th-2 response as well as development of other diseases accompanied with a high 
Th-2 response (e.g., UC) (22, 116). The hypothesis that UC could be a Th-2 
predominated type of inflammation was supported by the presence of high 
antibody production and increased levels of IL-5 in UC (44). The predominance of 
a Th-2 response elicited in vivo, would result in high and persistent antibody 
production (including that of lgE class), as well as the recruitment, activation, and 
prolonged survival of eosinophils and mast cells at the site of antigen exposure or 
inflammation (29). 
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Swine Dysentery: A Model for Inflammatory Bowel Disease? 
Using animal models for human IBD could provide vital information about 
disease pathogenesis, regulation, treatment and prevention. Murine models of 
mucosal inflammation demonstrate some of the proposed cytokine effects and 
other aspects of this disease. Colitis can be induced after administrating toxic 
chemicals such as acetic acid, formalin, indomethacin or TNBS/ ethanol, as well as 
with materials containing polysaccharides, such as carageenan and dextran 
sulphate (116). Colitis may also be induced in mice by infectious agents such as 
Helicobacter, Cryptosporidium or S. hyodysenteriae (14, 68, 153). In addition to 
these models, the development of gene knockout in mice has enabled examining 
the importance of cytokines in these diseases (e.g., IL-2 IL-10 or IFN-y knockout 
mouse) (24, 84, 121 ). The development of additional animal models for IBD is 
necessitated because no one model completely covers all the aspects associated 
with this disease process (116). 
A disease in swine known as swine dysentery (SD) is characterized by 
severe inflammation of the bowel. Microscopically, lesions are associated with 
excessive infiltration of inflammatory cells, gland hyperplasisa and dilation, 
superficial epithelial cell erosion and inflammatory cell exudation in the cecal 
lumen (60, 95). SD is a mucohemorrhagic diarrheal disease characterized by 
inflammation, excess mucus production and necrosis of the large intestine. The 
etiological agent of SD is known as Serpulina hyodysenteriae (158). Serpulina 
hyodysenteriae challenge in mice is used as a small animal model for SD as they 
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develop a lesion similar to that which occurs in swine (99). During SD, there is an 
extensive infiltration of inflammatory cells in the lamina propria after Serpulina 
hyodysenteriae challenge. Experiments have also shown that the phenotype and 
functional activity of T lymphocytes isolated from the inflamed intestine are altered 
following the oral inoculation of mice with Serpulina hyodysenteriae. Changes in 
the activity of T lymphocytes induced the increased production of IFN-y (45), which 
is similar to what has been described in CD. 
Disease caused by S. hyodysenteriae in either mice or pigs may share 
some predisposing factors that are described for IBD in humans especially CD. 
Although the causative agent of SD has been identified, predisposing or 
accelerating factors play an important role in this disease. For example, dietary 
changes have been clearly demonstrated to enhance the onset and the severity of 
lesions in the SD murine model (100). In other studies changing the diet to a highly 
digestible diet inhibited or prevented the onset of clinical signs or colonic lesions in 
swine experimentally infected with S. hyodysenteriae (114, 131). It was suggested 
that a highly digestible diet increases the pH of the large intestine, alters the 
composition of the normal flora and interferes with the colonization of S. 
hyodysenteriae (131 ). The underlying reason as to why mice develop lesions more 
quickly while maintained on a nutritionally complete, defined diet is not fully 
appreciated. One explanation suggested that this diet causes an increase in the 
number of S. hyodysenteriae in the colon due to the change in a type of normal 
flora present in the intestine (100). Another explanation may be that the high 
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glucose level in this diet leads to a high glucose level in the blood. This high 
glucose level may down-regulate corticosteriods in the liver. This would reduce the 
anti-inflammatory capacity and facilitate onset of disease. The exact explanation of 
the diet's effect is not well defined. However, the use of this diet has produced a 
more reproducible as well as more rapid onset of S. hyodysenteriae lesion in the 
murine model of SD. 
The genetic factors that effect IBD in humans (58, 73) have also been 
demonstrated to affect the susceptibility of mice to S. hyodysenteriae. For example, 
it has been shown that C3H/HeJ, CF-1, and Ta:CF-1 are sensitive to S. 
hyodysenteriae infection but to varying degrees (60, 140) while BALB/cByJ mice 
seem to be resistant to the onset of lesions (99). However, BALB/cByJ mice 
became sensitive to infection by changing the diet (100). 
Finally, the mechanisms of pathogenesis associated with the host response 
of pigs or mice infected with S. hyodysenteriae are proposed to be similar to those 
occurring as a consequence of idiopathic, chronic intestinal inflammation in 
humans (4). There is unclear information about the host-immune response in SD, 
nevertheless, T lymphocyte cytokines have been implicated as contributors to the 
inflammation. The same aspects are involved in IBD and other colitis-types of 
diseases. From the previous discussion, the type of immune response that is 
evoked after S. hyodysenteriae infection either in pigs or in mice shows some 
similarity with IBD in humans and other animal models of colitis. Therefore, this 
may open the way for using the animals infected with S. hyodysenteriae as an 
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animal model for IBD. This correlation may be employed to clarify some of the 
inflammatory reactions that occur in these diseases. 
Immune Response in Swine Dysentery 
The role of cell-mediated immunity in swine dysentery, IBD in humans and 
animal models of IBD is not well defined. Generally, T-cell activation is considered 
as a major feature which differentiates chronic from acute colitis (88). The 
development of cell-mediated immunity during the course of swine dysentery has 
been described, but the response has not been demonstrable during the acute 
phase of the disease. The induction of a delayed-type hypersensitivity reaction 
(DTH) in pigs infected with S. hyodysenteriae has been demonstrated by the 
recruitment and activation of macrophage (57). Additionally, mesenteric lymph 
node (MLN) and lamina propria (LP) T cells from mice challenged with S. 
hyodysenteriae were found to be active at 10 days post-infection (Pl) , but not at 3 
days Pl (45). In the same study MLN and LP lymphocytes recovered from mice 
infected with S. hyodysenteriae showed an increase in IFN-y secretion after in vitro 
stimulation with S. hyodysenteriae or Bacteriodis vulgatus whole cell antigens. This 
study showed an increase level of IFN-y cytokine production only at 10 days after 
infection which might indicate a possible correlation between the chronicity of the 
lesion and the presence of the Th-1 response. This also may indicate the 
involvement of a DTH-like response in the inflammatory lesions of SD. This study 
supports the hypothesis that T cells do not contribute to inflammatory response 
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during the acute phase of the disease, which is the same that was described for 
IBD in human and other colitis models. 
The factors that cause T-cell activation to occur later in this inflammatory 
process are still unclear. The cells that seem to be important in the acute phase of 
these diseases are leukocytes (104). It is clear that the characteristic features of 
early microscopic inflammatory lesions are leukocyte infiltration in the lamina 
propria (68). The infiltration of neutrophils into the cecal mucosa was observed by 
24 hrs following S. hyodysenteriae infection, and the numbers of neutrophils 
continued to increase through 48 hrs Pl. Recently, it has been shown that 
neutrophils have the ability to produce IFN-y which may contribute to the 
development of a biased Th-1 cellular response characteristic of inflammatory 
diseases of the bowel ( 104). It is well known that the in vitro as well as in vivo 
presence of IFN-y predisposes the development of Th-1 cells from naive T cells. 
The importance of neutrophils in the development of inflammatory diseases of the 
bowel has been shown by blocking neutrophil infiltration into a lesion using 
monoclonal antibodies to ~1 or ~2 integrins (68). 
The role of humoral immunity in SD is still unclear. The induction of S. 
hyodysenteriae-specific lgG, lgA, lgM or intestinal lgA antibody responses following 
infection has been reported (39, 68, 118, 133). Some studies have shown that the 
presence of these antibody responses is equivalent with respect to protection or 
lack thereof. Serum antibodies specific for the outer membrane lipoprotein (OML) 
of S. hyodysenteriae have been shown to inhibit the in vitro growth of S. 
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hyodysenteriae (98, 145). However, immunization of pigs with an outer membrane 
fraction induced only partial protection from the development of SD (152). Other 
studies have suggested that the presence of serum antibody specific for S. 
hyodysenteriae has little benefit for protection but simply indicates that the pig has 
been exposed to the organism (118). Several investigations have used serum 
antibody as a diagnostic tool to identify infected pigs as well as the serotype of S. 
hyodysenteriae (7, 133). 
Swine Dysentery Control and Vaccine Development 
Swine dysentery is an economically important disease in swine-producing 
countries. It causes high morbidity and mortality (142). In order to minimize the 
economic impact of SD, several methods to control this disease are recommended. 
Hygenic measures and use of anti-microbials are currently the primary approaches 
used to prevent SD in susceptable herd. However, these measures contribute to 
economic losses caused by this disease. 
To decrease the probability of introducing the bacteria into a non-infected 
herd, new pigs should be quarantined prior to introduction into the herd (49). 
Sanitation procedures should also be taken to avoid the introduction of infected 
feces. This route of contamination could occur via contaminated boots of the 
workers, coveralls and farm equipments. Maintaining a healthy and minimally 
stressed herd is considered to be an important factor for prevention. Anti-microbial 
chemicals and antibiotics such as organic arsenicals, carbadox, dimetridazole, 
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ronidazole, lincomycin, and tiamulin have been reported to be effective in the 
treatment of swine dysentery (81 ). 
An alternative approach to controlling SD could be achieved through 
vaccination. Because some pigs are protected against re-infection (143), the 
induction of protective immune response against this disease is possible. If swine 
are protected by vaccination, the need for drugs and the problems associated with 
drug residues could be reduced or avoided. However, control of SD by vaccination 
needs to be refined. Attempts to develop efficacious vaccines for SD have varied 
from promising results to disappointing or ineffective results. For example, 
vaccination of pigs with a whole cell bacterin of S. hyodysenteriae adjuvanted with 
mineral oil resulted in the exacerbation of lesions (107). Some publications 
reported the induction of partial protection following vaccination (56). The use of a 
hemolytic negative mutant of S. hyodysenteriae was effective in decreasing clinical 
signs and lesion severity, as well as in decreasing the period of bacterial shedding 
(56). Parenteral administration of whole cell bacterins or subunits of S. 
hyodysenteriae has also been reported to provide partial protection (39, 109). This 
partial protection could be improved through multiple injections of the vaccine (48). 
In other studies, parenteral immunization with killed whole cells followed by an oral 
administration of live avirulent S. hyodysenteriae gave good protection (72). The 
use of recombinant DNA vaccines from the different antigenic components of S. 
hyodysenteriae (i.e. recombinant hemolysin TlyA) also provide some promising 
results (56, 144). 
32 
One of the problems facing vaccine development is an inability to immunize 
against all potential serotypes of the pathogen (21, 61 ). Recombinant DNA vaccine 
development is attempting to cover all potential proteins or epitopes in all 
serotypes in order to overcome this serotype specific protection (56, 142). If 
mucosal immunity is responsible for protection in this disease, it will create another 
problem for SD vaccine development. The involvement of mucosal immunity opens 
the possibility of oral tolerance development to the orally adminstrated proteins 
(79). The combination of oral adjuvants such as cholera toxin with these antigens 
(51) or incorporation into microcapsules (i.e. hydrogels) (54) may overcome this 
problem. The oral tolerance problem also could be solved by oral administration of 
live attenuated vaccine as in the case of deletion of mutant bacteria or after the use 
of delivery systems (i.e. bacterial carrier) for the recombinant DNA vaccines (142). 
These possibilities indicate that effective vaccine development requires more work 
to be undertaken in order to identify the virulent factors and/or protective antigens 
including LPS, hemolysin, proteases (142) and/or specific surface antigens (15, 16, 
152). At the same time, follow-up vaccination and challenge studies should be 
undertaken with different vaccine preparations (142). Many studies have shown 
that the preparation of the vaccine, the dose, the route of vaccine immunization as 
well as the adjuvant used could affect the efficacy of any vaccine. 
The involvement of the immune system in the development of inflammatory 
disease of the bowel especially swine dysentery is poorly understood. The type of 
immune response in term of humoral, cellular, mucosal or systemic response that is 
required for prevention of SD needs further investigation (142). More information 
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concerning this point may lead to understanding the pathogenesis of the disease 
and to developing an effective vaccine or treatment. 
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MATERIALS AND METHODS 
Mice 
Eight to 16 week-old, male or female C3H/HeOuJ mice were used in this 
study. The C3H/HeOuJ strain was originally purchased from Jackson Laboratories, 
Bar Harbor, ME. Mice for this work were obtained from breeding colonies maintained 
under controlled conditions at the Laboratory Animal Resource Facility, Iowa State 
University. All animal studies were approved by the Iowa State University Committee 
on Animal Care and Use. 
Dietary Regimen 
Mice were maintained on mouse lab chow (MLC) #5010 (Purina Mills Inc., St. 
Louis, MO) prior to the initiation of each trial. Two days before infection (-2 DPI), the 
MLC was removed and replaced with a nutritionally complete, defined diet (Teklad 
85420, Harlan, Madison, WI). 
Bacteria and Infection 
Serpulina hyodysenteriae strain B204 was grown under anaerobic conditions 
in trypticase soy broth (TSB) (BBL Microbiology Systems, Cockeysville, MD) 
supplemented with 5% horse serum (Hyclone laboratories, logan, UT), 0.5% yeast 
extract (BBL) and VPI salts. All cultures used for infection had been passed in vitro 
less than 25 times. Highly motile (>95%) spirochetes were enumerated using a 
Petroff-Hauser counting chamber. Mice were administered 1 dose of 1x108 bacteria 
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in 0.5 ml of TSB via gastric intubation. Feed was removed for approximately 5 hours 
prior to infection and returned within 30 minutes post-challenge. 
Vaccination Protocols 
S. hyodysenteriae strain B204 were grown in TSB, washed 3 times in 
phosphate buffer saline (PBS), counted and disrupted by sonication. The pH was 
adjusted to 1.9 by adding 1 N HCI. The solution was digested with pepsin at 5 
mg/1010 S. hyodysenteriae and incubated for 24 hat 37°C, pH was adjusted to 7.1 
with 1 N NaOH and stored at -20°C. The vaccine preparation was then sterilized by 
irradiation (double pass at 3 rpm conveyors speed, energy 10 Mev and power level 
10 Kw). Mice were vaccinated intramuscularly (50 µL volume) with either 1, 5 or 10 
µg (protein content) of the pepsin digested preparation. 
Experimental Design 
The vaccination and challenge regimen is summarized in Table 2. On the day 
of challenge, mice were anesthetized with 0.3ml ketamine (2 µg/ml) and 300 µL of 
blood collected from their retro-orbital sinus. Twenty-two days later, mice were 
euthanized by C02 asphyxiation at different time points post infection 5, 14, 22, 35 
DPI. Cecal lesions were scored as shown in Figure 1. Anaerobic bacteriologic 
examination of cecal contents was performed by inoculation onto BJ blood agar 
medium. At 22 days post infection, serum samples were obtained and stored at -
20°C for subsequent antibody analysis. The spleen and mesenteric lymph node from 
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Table 2. Experimental design 
First vaccination dose Second vaccination dose No. mice 
Group µg/mouse (-26 DPI) µg/mouse (-12 DPI) Challenged per group 
0 0 8 
2 0 0 + 10 
3 5 + 10 
4 5 5 + 10 
5 10 10 + 8 
each mouse were separately collected for further in vitro stimulation with the S. 
hyodysenteriae WCS and Concanavilin A (Con A). 
Lymphocyte Isolation and Culture 
Mesenteric lymph nodes and spleen were excised, dispersed into a single cell 
suspension and washed once in RPMI 1640 (Fisher Scientific, Pittsburgh, PA). 
Lymphocytes (2 X 106 cells/ml) were cultured in the presence of 10 µg/ml (dry 
weight) of 8204 whole cell sonicate (WCS) or 5 µg/ml Con A in complete medium 
(RPMI 1640, 10 mM HEPES, 10% FBS (Atlanta Biologics, Atlanta, GA), 1 mM 
sodium pyruvate (Sigma), 0.2 mM 2-mercaptoethanol (Sigma) and essential and 
non-essential amino acids). Cells were incubated in round bottom 96 well microtiter 
plates (Falcon, Becton-Dickinsoni, Lincoln Park, NJ) at 37°C in 5% C02. 
Supernatants were collected after 48 to 72 hr and stored at -20°C prior to cytokine 
analysis. 
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Figure 1. Representative examples of gross cecal lesions from mice infected with 
Serpulina hyodysenteriae. Cecal Scores (from right to left): 0 - no gross lesion; 1 -
excess intraluminal mucus; 2 - excess intraluminal mucus and atrophy of the cecal 
apex; 3 - excess intraluminal mucus and cecal atrophy 
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Lymphocyte Blastogenesis 
Cell cultures were isolated and cultured in the presence of S. hyodysenteriae 
WCS, Con A, medium alone as described previously. Plates with Con A stimulation 
were incubated for 2 days while the plates were stimulated with the S. 
hyodysenteriae WCS and incubated for 4 days. After each incubation period, 0.5 µCi 
of methyl [H 3] thymidine (specific activity 6.7 Ci mmole-1, Amersham Life Science, 
Arlington Hieghts, IL) in 1 OµI of medium was added to each well and plates 
incubated for an additional 20 hr. The well contents were harvested onto glass fiber 
filters with a PHO harvester (Cambridge Technology, Cambridge, MA) and 
incorporated radioactivity was measured by liquid scintilation counting. Treatments 
were run in triplicate and stimulation index (SI) calculated by dividing counts per min 
of stimulated wells by counts per min of non-stimulated wells. Data are presented as 
average of SI± SEM. 
Anti- S. hyodysenteriae Strain 8204 Specific lgG1 and lgG2a 
Antibody Response 
lmmulon II microtiter plates (Corning, Park Ridge, IL) were coated with 1.5 
µg/well (dry weight) of S. hyodysenteriae strain B204 WCS diluted in carbonate 
buffer (pH 9.5). Plates were incubated at 4°C overnight and blocked with 1 % gelatin 
in PBS. Serum samples (1: 125) were added to appropriate wells and incubated at 
37°C for 1.5 hr. Plates were washed and isotype specific alkaline phosphatase-
conjugated goat anti-mouse lgG1 or lgG2a (1:1000) (Southern Biotechnology 
Associates, Inc., Birmingharm, AL) added to wells and incubated for 1 hr at 37°C. 
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Alkaline phosphatase substrate (Sigma 104) (1 mg/ml) was added in substrate 
buffer. The results are presented as O.D. values (405 nm). 
ELISA for Detection of IFN-y, IL-10 or TGF-~ 
Cell cultures received either media alone (non-stimulated), Con A, or S. 
hyodysenteriae strain 8204 WCS as described previously. IFN-y or IL-10 
concentrations in the culture supernatants were measured using a sandwich ELISA. 
Briefly, lmmulon II 96 well plates were coated with capture antibody (rat Mab XMG 
1.2 for IFN-y or rat Mab JES5-2A5 for IL-10) (Pharmingen, San Diego, CA) at 2 µg/ 
ml in carbonate buffer (pH 9.5) overnight at 4°C, blocked with 1 % gelatin for 1 hr at 
37°C and 100 µL of culture supernatant diluted either 1 :2 or 1 :4 added to wells and 
incubated for 1 hr at 37°C. For IFN-y, plates were sequentially incubated for 1 hr at 
37° C with 100 µL of a 1 :2000 dilution of rabbit anti-mouse IFN-y antibodies (gift 
from Dr. Randy Sacco at NADC, Ames, IA) followed by 100 µL alkaline phosphatase 
conjugated donkey anti-rabbit immunoglobulin (Jackson, West Grove, PA). For IL-10 
detection, biotinylated rat anti-mouse IL-10 (SXC-1) (Pharmingen) was added, the 
plates were washed and then alkaline phosphatase conjugated streptavidin 
(Southern Biotechnology Associates) was added. Plates were then incubated with 
alkaline phosphatase substrate (Sigma 104) and the color change quantified by 
measuring absorbance at 405 nm. Concentrations of IFN-y and IL-10 were estimated 
from standard curves generated using rlFN-y or rll-10, respectively,.(Pharmingen) 
40 
For TGF-P detection in the culture supernatants from spleen and MLN lymphocytes, 
a TGF-P ELISA kit was purchased from R&D systems, Inc, Minneapolis, MN. 
Analysis was performed as described by the manufacturer and the amount of TGF-
P was recorded in pg/ml. 
Statistical Analysis 
Statistical evaluation was performed by one-way analysis of variance, Tu key-Kramer 
multiple comparison tests using a commercially available statistical program (lnStat 
2.00, GraghPAD Software, San Diego, CA). 
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RESULTS 
Colonization and Persistence of S. hyodysenteriae 
Infection after Vaccination 
Bacteriological culture of cecal content from mice challenged with S. 
hyodysenteriae was conducted in order to evaluate the ability of vaccination to 
prevent colonization. The presence of p hemolytic spirochetes on B-J blood agar 
plates was considered positive for S. hyodysenteriae. At 22 DPI, all challenged mice 
were culture positive for S. hyodysenteriae regardless of the vaccination regimen. 
The non-immunized I non-challenged mice were all culture negative for S. 
hyodysenteriae. 
Gross Lesion 
The severity of cecal lesions in mice infected with S. hyodysenteriae was 
evaluated using the cecal scoring system depicted in Figure 1. The cecal scores 
were divided according to the severity, where scores 0 and 1 were considered as no 
lesions to mild lesions and represented as protected scores. The moderate to severe 
lesions (scores 2 and 3, respectively) were represented as non-protected scores. 
Mice were challenged with S. hyodysenteriae strain 8204 as previously described. 
Cecal scores were obtained from several experiments at different time points (e.g., 
5, 14, 22 and 35 DPI) (Figure 2). The best protection outcome based on cecal 
scores was achieved at 22 DPI, where the difference of the cecal scores between 
the vaccinated, infected mice and the non-vaccinated, infected mice was significant 
(P< 0.05). 
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Figure 2. Cecal scores of mice infected with S. hyodysenteriae strain 8204 at 
different time points after infection. Each value represents the mean value for each 
time point. The non-vaccinated, infected groups contained 13 mice at 5 DPI, 13 mice 
at 14 DPI, 26 mice at 22 DPI and 5 mice at 35 DPI. The vaccinated, infected groups 
consisting of 13 mice at 5 DPI, 13 mice at 14 DPI, 33 mice at 22 DPI and 5 mice at 
35 DPI, ±SEM. *P< 0.05. Only the successful vaccination protocols that gave> 60% 
protection at 22 DPI was included. 
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Cecal scores of mice sacrificed at 22 DPI were averaged and are listed in Table 3. 
The non-vaccinated, non-infected mice (group 1) were free of lesions. At 22 DPI, the 
non-vaccinated, infected mice as well as the vaccinated, infected mice (group 3) 
demonstrated moderate to severe lesions with less than 30% protection provided by 
the vaccine. The vaccinated, infected mice in groups 4 and 5 had less severe 
lesions than the control mice (group 1 and 2) and demonstrated approximately 60% 
protection from disease (P<0.01 ). Samples from group 4 and 5 were used for further 
analysis and were considered as one experimental unit (i.e., vaccinated, infected 
group). 
Table 3. Cecal scores and the percentage of protection for mice challenged with S. 
hyodysenteriae 
1st vaccination 2nd vaccination 
dose dose No. mice Cecal score Protection 
Group µg/mouse µg/mouse Challenged Per group (average) (%) 
(-26 DPI) (-12 DPI) 
1 0 0 8 0 NA 
2 0 0 + 10 2.56 0 
3 5 + 10 2 30 
4 5 5 + 10 60 
5 10 10 + 8 1.125 62 
Serum lgG1 and lgG2a Humoral Response to S. hyodysenteriae 
In order to demonstrate which type of immune response is activated following 
challenge, antigen specific serum antibody responses to S. hyodysenterteriae were 
assessed. The antibody response at 22 DPI from was compared to the antibody 
response at day zero (i.e., day of challenge) (Figure 3). Both lgG1 and lgG2a 
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Figure 3. Antigen-specific serum lgG1 and lgG2a antibody response of mice 
challenged with S. hyodysenteriae. Serum samples were collected from infected 
mice (n=12) and from non-vaccinated, infected mice (n=12) and from vaccinated, 
infected mice (n=18) at 22 DPI. Serum was also collected from non-vaccinated, non-
infected mice (n=26) and from vaccinated, non-infected mice (n=29) at the day of 
challenge. Results shown as the average optical density at 405 nm± S.E.M. Values 
with different letters are statistically different P< 0.05. * P=0.055. 
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antibody responses to S. hyodesenteriae WCS were significantly higher in the non-
vaccinated, infected group when compared to the non-vaccinated, non- infected 
group (P< 0.0007). In addition, the antibody responses for vaccinated, infected mice 
were greater than that of the vaccinated, non-infected group (P< 0.0001 ). The 
difference between the lgG1 and lgG2a response was not significant in all groups 
(P> 0.05) except in the non-vaccinated, infected mice. In this group, S. 
hyodysenteriae-specific lgG2a response was greater (P= 0.0001) than the lgG1 
response. 
To show the effect of vaccination on antibody responses after infection, the 
serum antibody responses of non-vaccinated, infected mice (group 2) were 
compared to those of the vaccinated, infected mice (groups 4 and 5). The lgG2a 
response was significantly reduced in the vaccinated, infected group (P=0.0126) 
while the lgG1 response was significantly increased (P=0.031 ). Further analyses 
were conducted on the vaccinated and infected groups (group 4 and 5) in order to 
demonstrate the difference in the protection outcome that appeared after 
vaccination. The immunized animals that showed protection after vaccination (i.e., 
the 60% and the 62% protection in group 4 and 5) were compared with the non-
protected animals (i.e., the remaining 40% and 38% non- protected animals in group 
4 and 5) (Figure 4 ). The animals that showed protection after vaccination had a 
lower lgG2a response than the non-protected mice (P= 0.02), while the lgG1 
response in the protected animals showed no significant difference when compared 
to the lgG1 production in non-protected animals (P>0.05). 
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Figure 4. Antigen-specific serum lgG1 and lgG2a antibody response in the 
vaccinated, infected mice 22 days after challenge. This group was divided into two 
groups on the basis of protection from disease. Mice (n=10) with a score of 0 or 1 
were combined and considered to be protected from disease. Mice (n=8) with cecal 
scores of 2 or 3 were combined and considered as diseased. Data presented as the 
mean value for each group± S.E.M. Values with different letters are statistically 
different P< 0.005. 
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IFN-y, IL-10 and TGF-~ Production by Spleen and Mesenteric Lymph 
Node Cells in Response to S. hyodysenteriae Antigens 
In order to measure the antigen-specific induction of cytokines, cell culture 
supernatants were tested for the presence of IFN-y, IL-10 and TGF-P as a reflection 
of Th-1, Th-2 or Th-3 immune responses, respectively. IFN-y and IL-10 were 
produced in response to S. hyodysenteriae antigens from all the experimental 
groups except the non-vaccinated, non-infected group. lnterferon-y production from 
spleen cells in the non- vaccinated, infected mice were higher than the amount 
produced from the spleen cells in the vaccinated, infected mice (P= 0.001) (Figure 
5), while the IFN-y production by mesenteric lymph node cells demonstrated no 
differences (P> 0.05) (Figure 6). On the other hand, the IL-10 production from the 
mesenteric lymph node cells in the non- vaccinated, infected group were significantly 
lower than the vaccinated, infected groups (P= 0.0075) (Figure 7). While this trend in 
IL-10 production was not similar in the spleen cells where the difference did not have 
a statistical significance (P> 0.05) (Figure 8). Among the vaccinated, infected mice 
(groups 4 and 5) there was no difference in the cytokine production between those 
mice which were protected and those not protected by vaccination (data not shown). 
Antigen specific production of TGF-p in response to S. hyodysenteriae WCS by 
lymphocytes was determined for each experimental group. Despite the high 
production of this cytokine from splenic lymphocytes, there was no significant 
difference in the production of TGF-p among the experimental groups (data not 
shown). On the contrary, analysis of culture supernatants from MLN lymphocytes 
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Figure 5. In vitro I FN-y production by spleen cells stimulated with 10 mg/ml S. 
hyodysenteriae WCS antigen for 48 hrs. The IFN-y response in non vaccinated , 
infected mice was higher than that observed in the vaccinated mice. For control mice 
(non- vaccinated, non-infected), IFN-y production ranged from 0 to 3 ng/ml. Each 
value represents the mean value for each group, consisting of 8 mice for the non-
vaccinated, non-infected group, 12 mice forthe non-vaccinated, infected group and 
18 mice for the vaccinated± S.E.M. Values with different letters are statistically 
different P<0.001 
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Figure 6. In vitro IFN-y production by mesenteric lymphnode (MLN) stimulated with 
10 µg/ml S. hyodysenteriae WCS antigen for 48 hrs. For control mice (non-
immunized, non-infected), IFN-y production ranged from 0 to 3 ng/ml. Each value 
represents the mean value for each group, consisting of 8 mice for the non-
vaccinated, non-infected group, 12 mice forthe non-vaccinated, infected group and 
18 mice for the vaccinated, infected± S.E.M. Values with different letters are 
statistically different P< 0.05. 
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Figure 7. In vitro IL-10 production by mesenteric lymph node cells (MLN) stimulated 
with 10 µg/ml S. hyodysenteriae WCS antigen for 48 hrs. The IL-10 response in 
vaccinated, infected mice was higher than that observed in the non-vaccinated, 
infected mice. For control mice (non- vaccinated, non-infected), IL-10 production 
ranged from 0 to 1 ng/ml. Each value represents the mean value for each group, 
consisting of 8 mice for the non- vaccinated, non-infected group, 12 mice for the 
non-vaccinated, infected group and 18 mice for the vaccinated ± S.E.M. Values with 
different letters are statistically different P< 0.0075. 
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Figure 8. In vitro IL-10 production by spleen cells stimulated with 10 µg/m/ S. 
hyodysenteriae WCS antigen for 48 hrs. For control mice (non-vaccinated, non-
infected), IL-10 production ranged from 0 to 1 ng/ml. Each value represents the 
mean value for each group, consisting of 8 mice for the non-vaccinated, non-infected 
group, 12 mice for the non-vaccinated, infected group and 18 mice for the 
immunized± S.E.M. Values with different letters are statistically different P< 0.05. 
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showed that cells from vaccinated, infected animals secreted significantly (P<0.05) 
higher amounts of TGF-P than cells from mice which were non-vaccinated and 
infected (Figure 9). 
Proliferative Response of Spleen and Mesenteric Lymph Node 
Cells to S. hyodysenteriae Antigens as well as to Con A 
All treatment groups in two separate experiments, failed to demonstrate 
proliferative responses to S. hyodysenteriae antigens (i.e., stimulation index< 2). 
However, these cells proliferated in response to the Con A stimulation, and there 
was no significant difference in the stimulation index (SI) among all groups. 
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Figure 9. In vitro TGF-P production by mesenteric lymph node cells stimulated with 
S. hyodysenteriae WCS antigen. Each value represents the mean value± SEM for 
each group, non-vaccinated, non-infected group (n=3), non-vaccinated, infected 
group (n=5) and vaccinated infected group (n=18). Statistics: treatment groups with 
different letters are statistically different (p< 0.05). 
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DISCUSSION 
Serpulina hyodysenteriae is the causative agent of swine dysentery, a 
disease characterized grossly by local inflammation and mucohemorrhagic 
diarrhea, and microscopically by superficial epithilial erosion, lamina propria 
congestion, inflammatory cell inflitration and colonic crypt hyperplasia (55, 60, 95). 
In addition to pigs, other animals species have been used as a model for SD (64, 
139). These animals develop SD-like lesions and can be employed for testing 
different control and prevention procedures used aganist this disease. The best 
studied model for SD is the murine model (99). Generally, animals infected with S. 
hyodysenteriae are protected against re-infection (143). Thus, it is possible to 
induce a protective immune response against this disease. Consequently, the 
objective of this project was to determine whether lesions induced by S. 
hyodysenteriae in mice could be controlled through vaccination. 
Previous vaccine studies have shown that vaccination of pigs with a whole 
cell bacterin of S. hyodysenteriae may result either in exacerbation of lesions (107) 
or in partial protection (39, 109). Most of the time, evaluation of the efficacy of the 
immunization trails had focused on the humoral immune response that developed 
after vaccination. The induction of S. hyodysenteriae-specific lgG, lgA, lgM or 
intestinal lgA antibody responses in pigs following infection has been reported (39, 
68, 118, 133). In spite of that, these antibody responses were not correlated with 
protection. However, the presence of serum antibody specific for S. hyodysenteriae 
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may simply be an indication of expousre to S. hyodysenteriae (118). The inabilty to 
correlate the antibody response with protection aganist this disease suggested that 
other mechanisms of immunity (e.g., cellular or mucosal) might be involved in the 
resolution of S. hyodysenteriae lesions (142). 
A better understanding of the host-mediated immune response may aid in 
the unraveling of the pathogenesis of SD. Based on a previous study (45), it was 
speculated that the pathogenesis of chronic colitis in mice following infection with 
S. hyodysenteriae involved the induction of T cell-mediated hypersensitive 
immune, particularily, a biased Th-1 response. It was further anticipated that this 
biased Th-1 response could be regulated by use of an appropriate vaccination 
regimen. In order to achevie protection from colitis in mice, preliminary studies 
were performed using different vaccine formulations (e.g., whole cell bacterin vs 
proteinase digestion of WCS). Based on these experimental results, a pepsin-
digested S. hyodysenteriae WCS (PD-WCS) vaccine was employed. The 
mechanisms of protection induced following vaccination were examined by 
comparing measures of humoral and cellular immunity in naive and immunized 
animals following S. hyodysenteriae challenge. We hypothesize that development 
of S. hyodysenteriae -induced lesion was associated with a biased Th-1 response 
and vaccination will down-regulate this response through activation of regulatory T 
cells (i.e., Th-2 and Th-3 cells). The current study used IFN-y production by MLN 
and spleen lymphocytes and serum lgG2a antibody production as indicators of a 
Th-1 response while IL-10 production by MLN and spleen lymphocytes and serum 
56 
lgG1 antibody production indicated a Th-2 response (45). Th-3 responses were 
assesed through measuring the TGF-~ production in the spleen and MLN cell 
culture supernatant stimulated with the S. hyodysenteriae WCS. 
Based on antibody responses, vaccination with PD-WCS induced neither a 
Th-1 nor a Th-2 biased response prior to or following infection. However, the serum 
lgG1 response of the vaccinated, infected mice was greater than the lgG1 
response in non-vaccinated, infected animals suggesting that mice had been 
primed for the development of a Th-2 response. At the same time, vaccination 
resulted in a lower lgG2a response than the lgG2a response in non-vaccinated 
mice following challenge. Thus, the serum antibody response indicated that a Th-2 
immune response was favored in mice protected from disease by vaccination. 
Similarly, in vitro IFN-y and IL-10 production by spleen and MLN cells stimulated 
with S. hyodysenteriae WCS antigens could be used to determine the type of CM I 
response that was stimulated after S. hyodysenteriae challenge as well as after 
vaccination. 
Regardless of the tissue source (e.g., spleen vs MLN), the S. 
hyodysenteriae-specific induction of either IFN-y or IL-10 indicated that vaccination 
attenuated the Th-1 response as well as increased the Th-2 response. After S. 
hyodysenteriae challenge, IFN-y production by splenic lymphocytes from 
vaccinated mice was lower than that by cells recovered from non-vaccinated mice. 
On the other hand, the IL-10 production by MLN lymphocytes in the vaccinated, 
infected animals was higher than that of MLN cells from infected only animals. The 
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use of lgG2a and IFN-y production as well as lgG1 and IL-10 production as 
indicators of Th-1 and Th-2 responses, respectively, demonstrated that a biased 
Th-1 response clearly accompanied the development of moderate to severe 
lesions in the non-vaccinated, infected mice. It was also shown that the ability to 
control the magnitude of Th-1 response through vaccination resulted either in 
protection or in the development of less severe lesions. At the same time, this 
amelioration of colitis was associated with a Th-2 response. 
While Immunization with the PD-WCS failed to prevent the acute lesions 
(i.e., 5 DPI), successful! resolution of cecal lesions was demonstrated with low to 
moderate doses of PD-WCS. Analysis of the antibody response and cytokine 
production in the experimental groups at 5 DPI showed the absence of any 
significant difference between all groups (data not shown). In comparison to 
protected mice, vaccinated animals which had not resolved their cecal lesions 
failed to down regulate the magnitude of the Th-1 response as evidenced by a high 
lgG2a response. These results demonstrated the correlation between reducing the 
Th-1 response and protection from S. hyodysenteriae-induced colitis. At the same 
time, Th-2 responses were elevated by vaccination regardless of protection. 
Unfortunately, this conculsion is based solely upon the comparison of lgG1 v.s 
lgG2a antibody responses because the cytokine response (i.e. , IFN-y and IL-10) 
showed no difference between the vaccinated, protected and non-protected mice. 
The regulatory mechanism involved in the induction of Th-1 or Th-2 
responses are not clearly defined. Because Th-1 and Th-2 development and 
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regulation are considered an essential factor in immune mediated diseases, the 
appropriate regulation of these responses may determine the outcome (i.e., health 
v.s. disease) (134). In the present study, analysis of the serum antibody response of 
vaccinated, infected mice showed that the presence of a Th-2 response (i.e., lgG1 
and IL-10) did not completely prevent the induction of a Th-1 response (i.e. lgG2a 
and IFN-y) following challenge. In other words, the vaccinated mice developed a 
balanced Th-1 and Th-2 immune response following infection in comparison to the 
polarized Th-1 response observed in the non-vaccinated, infected mice. The 
presence of both T helper responses indicated that the relationship between Th-1 
and Th-2 can not be defined by the classical model previously described (93) 
(Figure 10). Recently, an alternative model has evolved in which the Th-1/Th-2 
relationship was re-evaluated (Figure 11) (93). In this new model, the 
microenviroment in which an appropriate effector T cell response develops, is 
determined by the nature of the immune defense required for disease resistance. 
Furthermore, responses which develop within the correct microenviroment will 
provide beneficial inflammatory responses necessary for recovery from disease. 
The new model described acute immunity as uncontrolled responses which 
include activation and recruitment of non-specific inflammatory effectors (e.g., 
polymorphonuclear cells, prostaglandins, complement, macrophages). 
Subsequently, this non-specific response is subplanted by an 
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Figure 10. The classical cross-regulatory model for Th-1 /Th-2 cells consider the 
production of IFN-y and IL-10 from Th-1 cells and Th-2 cells, respectively to have an 
antagonistic effect on their existence. 
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Figure 11. Regulation of the immune response during disease showed that the early 
immune responses were aggressive and could have a non-specific inflammatory 
effectors (i.e., macrophage and esinophil mediated response). These responses 
must be regulated in order to decrease the early destructive inflammatory responses 
(i.e., Type I or IV hypersensitivity reaction). IL-10 appears to down-regulate this 
noxious inflammatory response and enhance a less aggressive immune defense 
mechanism characterized by antigen-specific effector response. 
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antigen-specific response mediated by regulatory cytokines (e.g. , IL-10). In 
addition, this model suggested that these cytokines often displayed overlapping 
regulatory effects. For example, the role of IL-10 would no longer simply have an 
inhibitory effect on Th-1 cells and a stimulatory effect on Th-2 cells. Several studies 
have shown that IL-10 could inhibit or stimulate Th-1 and Th-2 responses 
depending on the amount and timing of cytokine production (18, 28, 59, 93). In 
other words, IL-10 has a regulatory effect on both humeral and cellular aspects of 
the immune response (93) . 
This view of Th-1 /Th-2 paradigm begins to explain the frequently observed 
in vivo data that do not fit within the simple classical Th-1/Th-2 paradigm. 
Accordingly, in the early immune phase in this disease (i.e., SD), the activation and 
recruitment of antigen-nonspecific inflammatory effectors was higher than the 
antigen specific response. With time following infection, non-specific effector Th-1 
response would be regulated in vaccinated mice. Thus, these mice would 
demonstrate both Th-1 and Th-2 responses. This may explain why vaccination did 
not completely ameliorate the Th-1 response as measured by lgG2a and IFN-y 
production. In addition, this new Th-1/Th-2 paradigm showed that both biased Th-1 
and I or Th-2 responses may serve to synergize tissue destructive events through 
type IV or type I hypersensitivity, respectively (34, 91 ). This would explain why 
some vaccinated mice with a demonstrable Th-2 response developed chronic, 
severe lesions rather than resolution of disease (personal communication, M. J. 
Wannemuehler). This may be similar to the observation in human UC, which 
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showed that lesion development was correlated to a biased immune response 
towards a Th-2 response (71 ). Therefore, sucessful vaccination against SD should 
provide an appropriate Th-2 response (i.e. , balanced with Th-1 response). 
The exact reason for lesion resolution achieved after using the proteinase-
digested S. hyodysenteriae WCS vaccine is not fully understood. However, two 
concepts may explain the protection that was achieved through the use of 
proteinase-digested bacterin instead of whole cell bacterin. First, it is possible that 
the proteinase digestion of bacterial whole cells simply provided for low dose 
immunization, thus, reducing the likelyhood that hypersensitivity to immuno-
dominant immunogens would develop. In other models, low doses of antigen have 
been shown to induce a Th-2 type of response (27). Second, the digestion of the 
WCS may generate altered peptide ligands, which have been shown to provoke 
alternative immune responses than those induced by native immunogens (105). In 
support of the benefits of low dose immunization, it was shown that an extremely 
low dose of intact, whole cell bacterin (0.05 µg/ mouse) induced protection similar 
to that acheived with 5 µg dose of PD-WCS preparation (personal communication, 
M.J. Wannemuehler). This may indicate that low dose priming of the immune 
response facilitates induction of immuno-regulatory Th-2 responses and may be 
more significant to immune-mediated protection than the presence of altered 
peptide ligands. 
In order to explain how a parental vaccine is able to protect against a 
mucosal pathogen, it may be necessary to understand lymphocyte trafficking as 
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well as the induction of mature effector T cells. The current study showed that 
infection with S. hyodysenteriae induces the development of a Th-1 response. After 
presentation of S. hyodysenteriae antigen in the organized mucosal lymphoid 
tissues (OML T), one would expect that naive Th-0 cells will differentiated into 
precursor Th-1 (pTh-1) cells. These pTh-1 cells will then enter the draining MLN to 
complete maturation into Th-1 cells (i.e., IFN-y producing cells) (8, 20, 50). 
Afterwards, the mature Th-1 cells will leave the MLN and migrate through the blood 
to the effector compartment of the mucosa (e.g., lamina propria) where they may 
become activated and contribute to the inflammatory response (20). Some of these 
mature Th-1 cells will preferentially home back to the OML T as well as to the 
spleen (159). Thus, antigen-specific Th-1 cells will have the opportunity to 
encounter antigen in the OML T for a second time which will induce clonal 
expansion. This would allow the antigen-specific Th-1 cells to expand and to 
migrate to the MLN. These antigen specific T cells would more quickly re-enter the 
circulation without the need for further maturation. As a consequence, there would 
be few antigen-specific T cells in the MLN capable of producing IFN-y. This would 
explain the present observations in which a low IFN-y response was detected by 
MLN lymphocytes recovered from infected animals. On the other hand, IFN-y 
production by splenic lymphocytes of mucosal origin recovered from infected 
animals was higher than that from cells obtained from vaccinated animals because 
these mature T-helper cells home more effectively to the spleen than they do to the 
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MLN (159). This was supported by the presence of low amount of mucosa! T cells 
homing receptors (a4~7) on the memory T cells derived from the MLN (159). 
While homing or trafficking of antigen-specific lymphocytes may explain part 
of the observed data in the infected animals, it is possible that vaccination also 
directly affected the development and trafficking of Th-1 cells following challenge. It 
has been shown that lymphocytes primed in a peripheral LN will home 
preferentially to other lymph nodes including the MLN (159) which bear the 
features of both mucosa! and peripheral lymphoid organs (13). This implies that by 
injecting the PD-WCS vaccine intramuscularly (i.e., parental vaccination), we have 
established a population of antigen specific T cells which will effectively home to 
the MLN but not to the OMLT nor to the LP. 
It was our initial hypothesis that the use of PD-WCS vaccine would facilitate 
the induction of a Th-2 response rather than a Th-1 immune response. This was 
supported with the observation of higher IL-10 production from cells recovered from 
MLN of vaccinated mice than that from cells obtained from non-vaccinated mice. As 
a consequence of peripheral Th-2 cell induction , one would expect that 
vaccination will provide protection either by interfering with the maturation of the 
pTh-1 cell towards a Th-1 cell or through the inhibition of mature Th-1 cell activity in 
MLN. It has been demonstrated that Th-2 cells were unable to down regulate the 
mature Th-1 cells (Figure 12) (131 ). Thus, this will restrict their abi lity for blocking 
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Figure 12. The down-regulatory effect of Th-2 cells on development or activation of Th-
1 responses. Th-2 cells have only been shown to down-regulate the differentiation of Th-
0 cells into Th-1 cells. Th-2 cells do not inhibit the activation of mature Th-1 cells. 
However, Th-2 cells are able to inhibit mature Th-1 cells through augumentation of 
TGF-P production by Th-3 cells. 
66 
Th-0 differentiation towards Th-1 in the MLN. However, Th-2 cells could indirectly 
inhibit the mature Th-1 response through augmentation of TGF-P production from 
Th-3 cells (Figure 12) ( 131). This would explain the presence of antigen-specific 
TGF-P production by cells recovered from the MLN of vaccinated animals and not 
from cells obtained from mice which were not vaccinated. In this way, fewer Th-1 
cells will develop and migrate back to the mucosa while Th-3 cells will effectively 
migrate to the LP as well as to the OMLT (131) where they provide an additional 
immune-regulatory mechanism which begin to reduce the inflammatory response. 
In addition, it is not neccessary to hypothesize that Th-2 cells generated by parental 
vaccination home to the mucosa to block or down regulate inflammatory reactions. 
Finally, effective control of the biased Th-1 response which develops 
subsequent to S. hyodysenteriae infection will involve the down-regulation of non-
specific Th-1 responses but retain the antigen-specific Th-1 responses required for 
disease resolution. This down-regulation may result from a decrease in the number 
of Th-1 cells that were activated after infection. In addition, the induction of a Th-2 
response and TGF-P production in the MLN after vaccination indicate that there are 
multiple mechanisms regulating the Th-1 response: (1) Th-2 response may inhibit 
the maturation of pTh-1 into Th-1 cells mainly in the MLN (2) Th-3 response 
augumented by the presence of Th-2 response which is generated after 
vaccination, acts on activated Th-1 cells within the OML Tor the inflammatory site 
(e.g., LP). In this way, immunization aganist S. hyodysenteriae should be directed 
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towards priming a regulatory immune response rather than inducing a vigorous 
effector immune responses. 
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